<DOC>
	<DOCNO>NCT02044653</DOCNO>
	<brief_summary>The primary objective study - Part A : To explore optimal fix start dose dose interval GX-E2 - Part B : To evaluate proof concept ( POC ) GX-E2</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety GX-E2 Anemic Patients Diagnosed With Chronic Kidney Disease ( CKD )</brief_title>
	<detailed_description>The secondary objective study evaluate : - change red blood cell index anemic patient chronic kidney disease receive hemodialysis/peritoneal dialysis administer GX-E2 intravenously/subcutaneously - change reticulocyte index anemic patient chronic kidney disease receive hemodialysis/peritoneal dialysis administer GX-E2 intravenously/subcutaneously - safety GX-E2 administer intravenously/subcutaneously - incidence blood transfusion anemic patient chronic kidney disease receive hemodialysis/peritoneal dialysis administer GX-E2 intravenously/subcutaneously - Immunogenicity anemic patient chronic kidney disease receive hemodialysis/peritoneal dialysis administer GX-E2 intravenously/subcutaneously</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Written inform consent ≥18 yr age Chronic Kidney diseases hemodialysis , peritoneal dialysis Adequate transferrin saturation ( ≥20 % ) , serum ferritin ( ≥100g/dl ) Should receive Vitamine B12 ≥ 3 month first dose study agent Should receive Folate ≥3 month first dose study agent No erythropoietin ( EPO ) therapy within 2month plan first dose GXE2 Hb &lt; 10g/dL No EPO therapy within month plan first dose GXE2 Hb &lt; 10g/dL Uncontrolled hypertension Uncontrolled arrhythmia History acute chronic bronchospastic disease ( include asthma chronic obstructive pulmonary disease ) History hypersensitivity study drug similar drug aspartate aminotransferase/alanine aminotransferase ( ALT/AST ) &gt; 3 time Upper Normal Limit Normal ( UNL ) Absolute neutrophil count ≤ 1,500 per microliter ( uL ) Donation loss ≥400 milliliter ( mL ) blood within 8 week prior first dose Major surgery within 3 month Grand Mal epilepsy History drug alcohol abuse 6 month prior Screening Participation clinical investigation 4 week period prior dose Refractory erythropoiesis stimulate agent ( ESA ) treatment Systemic hematologic disease ( e.g . Pure red cell anemia , sickle cell anemia , myelodysplastic syndrome , hematologic malignancy , myeloma , hemolytic anemia )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Phase 2</keyword>
</DOC>